O	0	4	Dose
O	4	5	-
O	5	14	dependent
O	15	21	effect
O	22	24	of
B-intervention	25	32	aerobic
I-intervention	33	41	exercise
O	42	44	on
O	45	57	inflammatory
O	58	68	biomarkers
O	69	71	in
O	72	73	a
O	74	84	randomized
O	85	95	controlled
O	96	101	trial
O	102	104	of
O	105	110	women
O	111	113	at
O	114	118	high
O	119	123	risk
O	124	126	of
O	127	133	breast
O	134	140	cancer
O	140	141	.

O	142	151	Increased
O	152	158	levels
O	159	161	of
O	162	174	inflammation
O	175	178	are
O	179	189	associated
O	190	194	with
O	195	199	many
O	200	208	diseases
O	208	209	,
O	210	219	including
O	220	226	cancer
O	226	227	.

O	228	236	Physical
O	237	245	activity
O	246	249	can
O	250	255	lower
O	256	262	breast
O	263	269	cancer
O	270	274	risk
O	275	277	as
O	278	282	well
O	283	285	as
O	286	292	levels
O	293	295	of
O	296	308	inflammation
O	308	309	.

O	310	313	The
O	314	319	Women
O	320	322	In
O	323	329	Steady
O	330	338	Exercise
O	339	347	Research
O	348	349	(
O	349	354	WISER
O	354	355	)
O	356	362	Sister
O	363	368	trial
O	369	372	was
O	373	374	a
O	375	385	randomized
O	386	396	controlled
O	397	402	trial
O	403	407	that
O	408	420	investigated
O	421	424	the
O	425	432	effects
O	433	435	of
O	436	437	a
O	438	443	dosed
O	443	444	,
O	445	453	moderate
O	454	456	to
O	457	465	vigorous
O	465	466	,
O	467	474	aerobic
O	475	483	exercise
O	484	496	intervention
O	497	499	on
O	500	506	levels
O	507	509	of
O	510	522	inflammation
O	523	525	in
B-eligibility	526	539	premenopausal
I-eligibility	540	545	women
I-eligibility	546	549	who
I-eligibility	550	554	were
I-eligibility	555	557	at
I-eligibility	558	562	high
I-eligibility	563	567	risk
I-eligibility	568	570	of
I-eligibility	571	581	developing
I-eligibility	582	588	breast
I-eligibility	589	595	cancer
O	595	596	.

O	597	609	Participants
O	610	614	were
O	615	625	randomized
O	626	628	to
B-control	629	636	control
O	637	638	(
O	638	639	<
O	639	641	75
O	642	649	minutes
O	650	653	per
O	654	658	week
O	658	659	;
B-control-participants	660	662	41
O	663	671	patients
O	671	672	)
O	672	673	,
O	674	677	low
O	677	678	-
O	678	682	dose
O	683	691	exercise
O	692	693	(
O	693	696	150
O	697	704	minutes
O	705	708	per
O	709	713	week
O	713	714	;
B-intervention-participants	715	717	38
O	718	726	patients
O	726	727	)
O	727	728	,
O	729	731	or
O	732	736	high
O	736	737	-
O	737	741	dose
O	742	750	exercise
O	751	752	(
O	752	755	300
O	756	763	minutes
O	764	767	per
O	768	772	week
O	772	773	;
B-intervention-participants	774	776	37
O	777	785	patients
O	785	786	)
O	787	793	groups
O	793	794	.

O	795	798	The
O	799	800	5
O	800	801	-
O	801	810	menstrual
O	811	817	cycles
O	817	818	-
O	818	822	long
O	822	823	,
O	824	828	home
O	828	829	-
O	829	834	based
O	835	844	treadmill
O	845	853	exercise
O	854	866	intervention
O	867	876	gradually
O	877	886	increased
O	887	889	in
O	890	897	minutes
O	898	901	per
O	902	906	week
O	907	910	and
O	911	920	intensity
O	921	923	up
O	924	926	to
O	927	928	a
O	929	936	maximum
O	937	939	of
O	940	942	80
O	942	943	%
O	944	946	of
O	947	950	the
O	951	954	age
O	954	955	-
O	955	964	predicted
O	965	972	maximum
O	973	978	heart
O	979	983	rate
O	983	984	.

O	985	990	Blood
O	991	994	was
O	995	1004	collected
O	1005	1007	at
O	1008	1016	baseline
O	1017	1020	and
O	1021	1023	at
O	1024	1030	follow
O	1030	1031	-
O	1031	1033	up
O	1034	1037	and
O	1038	1045	assayed
O	1046	1049	for
O	1050	1059	chemokine
O	1060	1061	(
O	1061	1062	C
O	1062	1063	-
O	1063	1064	C
O	1065	1070	motif
O	1070	1071	)
O	1072	1078	ligand
O	1079	1080	2
O	1081	1082	(
O	1082	1086	CCL2
O	1086	1087	)
O	1087	1088	,
O	1089	1100	interleukin
O	1101	1103	10
O	1104	1105	(
O	1105	1107	IL
O	1107	1108	-
O	1108	1110	10
O	1110	1111	)
O	1111	1112	,
O	1113	1124	interleukin
O	1125	1127	12
O	1128	1129	(
O	1129	1131	IL
O	1131	1132	-
O	1132	1134	12
O	1134	1135	)
O	1135	1136	,
O	1137	1140	and
O	1141	1146	tumor
O	1147	1155	necrosis
O	1156	1162	factor
O	1163	1164	α
O	1165	1166	(
O	1166	1169	TNF
O	1169	1170	-
O	1170	1171	α
O	1171	1172	)
O	1172	1173	.

O	1174	1175	A
O	1176	1182	linear
O	1183	1187	dose
O	1187	1188	-
O	1188	1196	response
O	1197	1209	relationship
O	1210	1213	was
O	1214	1222	observed
O	1223	1226	for
O	1227	1230	the
B-outcome	1231	1246	proinflammatory
I-outcome	1247	1257	biomarkers
I-outcome	1258	1262	CCL2
O	1263	1264	(
O	1264	1265	%
O	1265	1266	Δ
O	1267	1269	of
O	1270	1271	-
O	1271	1272	5
O	1272	1273	.
O	1273	1275	44
O	1275	1276	%
O	1277	1279	in
O	1280	1283	the
O	1284	1291	control
O	1292	1297	group
O	1297	1298	,
O	1299	1300	-
O	1300	1301	0
O	1301	1302	.
O	1302	1304	03
O	1304	1305	%
O	1306	1308	in
O	1309	1312	the
O	1313	1316	low
O	1316	1317	-
O	1317	1321	dose
O	1322	1330	exercise
O	1331	1336	group
O	1336	1337	,
O	1338	1341	and
O	1342	1343	1
O	1343	1344	.
O	1344	1346	54
O	1346	1347	%
O	1348	1350	in
O	1351	1354	the
O	1355	1359	high
O	1359	1360	-
O	1360	1364	dose
O	1365	1373	exercise
O	1374	1379	group
O	1379	1380	)
O	1380	1381	,
B-outcome	1382	1384	IL
I-outcome	1384	1385	-
I-outcome	1385	1387	12
O	1388	1389	(
O	1389	1390	%
O	1390	1391	Δ
O	1392	1394	of
O	1395	1396	-
O	1396	1398	21
O	1398	1399	.
O	1399	1400	5
O	1400	1401	%
O	1402	1404	in
O	1405	1408	the
O	1409	1416	control
O	1417	1422	group
O	1422	1423	,
O	1424	1426	38
O	1426	1427	.
O	1427	1428	2
O	1428	1429	%
O	1430	1432	in
O	1433	1436	the
O	1437	1440	low
O	1440	1441	-
O	1441	1445	dose
O	1446	1454	exercise
O	1455	1460	group
O	1460	1461	,
O	1462	1465	and
O	1466	1468	25
O	1468	1469	.
O	1469	1470	8
O	1470	1471	%
O	1472	1474	in
O	1475	1478	the
O	1479	1483	high
O	1483	1484	-
O	1484	1488	dose
O	1489	1497	exercise
O	1498	1503	group
O	1503	1504	,
O	1504	1505	)
O	1506	1509	and
B-outcome	1510	1513	TNF
I-outcome	1513	1514	-
I-outcome	1514	1515	α
O	1516	1517	(
O	1517	1518	%
O	1518	1519	Δ
O	1520	1522	of
O	1523	1524	-
O	1524	1525	4
O	1525	1526	.
O	1526	1528	69
O	1528	1529	%
O	1530	1532	in
O	1533	1536	the
O	1537	1544	control
O	1545	1550	group
O	1550	1551	,
O	1552	1553	9
O	1553	1554	.
O	1554	1556	51
O	1556	1557	%
O	1558	1560	in
O	1561	1564	the
O	1565	1568	low
O	1568	1569	-
O	1569	1573	dose
O	1574	1582	exercise
O	1583	1588	group
O	1588	1589	,
O	1590	1593	and
O	1594	1596	15
O	1596	1597	.
O	1597	1598	7
O	1598	1599	%
O	1600	1602	in
O	1603	1606	the
O	1607	1611	high
O	1611	1612	-
O	1612	1616	dose
O	1617	1625	exercise
O	1626	1631	group
O	1631	1632	)
O	1633	1636	but
O	1637	1640	not
O	1641	1644	for
O	1645	1648	the
B-outcome	1649	1653	anti
I-outcome	1653	1654	-
I-outcome	1654	1666	inflammatory
I-outcome	1667	1676	biomarker
O	1677	1679	IL
O	1679	1680	-
O	1680	1682	10
O	1683	1684	(
O	1684	1685	%
O	1685	1686	Δ
O	1687	1689	of
O	1690	1691	5
O	1691	1692	.
O	1692	1694	05
O	1694	1695	%
O	1696	1698	in
O	1699	1702	the
O	1703	1710	control
O	1711	1716	group
O	1716	1717	,
O	1718	1719	6
O	1719	1720	.
O	1720	1722	05
O	1722	1723	%
O	1724	1726	in
O	1727	1730	the
O	1731	1734	low
O	1734	1735	-
O	1735	1739	dose
O	1740	1748	exercise
O	1749	1754	group
O	1754	1755	,
O	1756	1759	and
O	1760	1762	10
O	1762	1763	.
O	1763	1764	6
O	1764	1765	%
O	1766	1768	in
O	1769	1772	the
O	1773	1777	high
O	1777	1778	-
O	1778	1782	dose
O	1783	1791	exercise
O	1792	1797	group
O	1797	1798	)
O	1798	1799	.

O	1800	1803	For
B-outcome	1804	1806	IL
I-outcome	1806	1807	-
I-outcome	1807	1809	12
I-outcome	1810	1813	and
I-outcome	1814	1817	TNF
I-outcome	1817	1818	-
I-outcome	1818	1819	α
I-outcome	1819	1820	,
I-outcome	1821	1824	the
I-outcome	1825	1835	percentage
I-outcome	1836	1842	change
O	1843	1846	was
O	1847	1860	significantly
O	1861	1867	higher
O	1868	1870	in
O	1871	1874	the
B-outcome	1875	1878	low
I-outcome	1878	1879	-
I-outcome	1879	1883	dose
I-outcome	1884	1885	(
I-outcome	1885	1887	IL
I-outcome	1887	1888	-
I-outcome	1888	1890	12
O	1890	1891	:
O	1892	1893	P
O	1894	1895	<
O	1896	1897	.
O	1897	1900	001
O	1900	1901	;
O	1902	1905	and
O	1906	1909	TNF
O	1909	1910	-
O	1910	1911	α
O	1911	1912	:
O	1913	1914	P
O	1915	1916	=
O	1917	1918	.
O	1918	1920	01
O	1920	1921	)
O	1922	1925	and
B-outcome	1926	1930	high
I-outcome	1930	1931	-
I-outcome	1931	1935	dose
I-outcome	1936	1937	(
I-outcome	1937	1939	IL
I-outcome	1939	1940	-
I-outcome	1940	1942	12
O	1942	1943	:
O	1944	1945	P
O	1946	1947	<
O	1948	1949	.
O	1949	1952	001
O	1952	1953	;
O	1954	1957	and
O	1958	1961	TNF
O	1961	1962	-
O	1962	1963	α
O	1963	1964	:
O	1965	1966	P
O	1967	1968	<
O	1969	1970	.
O	1970	1973	001
O	1973	1974	)
O	1975	1983	exercise
O	1984	1990	groups
O	1991	1999	compared
O	2000	2004	with
O	2005	2008	the
O	2009	2016	control
O	2017	2022	group
O	2022	2023	.

O	2024	2032	Moderate
O	2033	2035	to
O	2036	2044	vigorous
O	2045	2052	aerobic
O	2053	2061	exercise
O	2062	2070	appeared
O	2071	2073	to
O	2074	2082	increase
O	2083	2089	levels
O	2090	2092	of
O	2093	2108	proinflammatory
O	2109	2119	biomarkers
O	2120	2122	in
O	2123	2124	a
O	2125	2129	dose
O	2129	2130	-
O	2130	2139	dependent
O	2140	2146	manner
O	2147	2149	in
O	2150	2151	a
O	2152	2162	population
O	2163	2165	of
O	2166	2173	healthy
O	2174	2179	women
O	2180	2182	at
O	2183	2187	high
O	2188	2192	risk
O	2193	2195	of
O	2196	2206	developing
O	2207	2213	breast
O	2214	2220	cancer
O	2220	2221	.

O	2222	2225	The
O	2226	2233	results
O	2234	2236	of
O	2237	2240	the
O	2241	2248	current
O	2249	2254	study
O	2255	2262	suggest
O	2263	2267	that
O	2268	2271	for
O	2272	2279	healthy
O	2280	2293	premenopausal
O	2294	2299	women
O	2299	2300	,
O	2301	2304	the
O	2305	2314	mechanism
O	2315	2317	of
O	2318	2325	reduced
O	2326	2332	breast
O	2333	2339	cancer
O	2340	2344	risk
O	2345	2353	observed
O	2354	2356	in
O	2357	2367	physically
O	2368	2374	active
O	2375	2386	individuals
O	2387	2390	may
O	2391	2394	not
O	2395	2397	be
O	2398	2399	a
O	2400	2406	result
O	2407	2409	of
O	2410	2417	reduced
O	2418	2424	levels
O	2425	2427	of
O	2428	2440	inflammation
O	2440	2441	.
